The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature
Abstract
Tumor neovasculature is a potential but, until very recently, unexplored target for boron neutron capture therapy (BNCT) of cancer. In the present report, we describe the construction of a vascular endothelial growth factor (VEGF)–containing bioconjugate that potentially could be used to target up-regulated VEGF receptors (VEGFR), which are overexpressed on tumor neovasculature. A fifth-generation polyamidoamine dendrimer containing 128 reactive amino groups was reacted with 105 to 110 decaborate molecules to produce a macromolecule with 1,050 to 1,100 boron atoms per dendrimer. This was conjugated to thiol groups of VEGF at a 4:1 molar ratio using the heterobifunctional reagent sulfo-LC-SPDP. In addition, the boronated dendrimer was tagged with a near-IR Cy5 dye to allow for near-IR fluorescent imaging of the bioconjugate in vitro and in vivo. As would be predicted, the resulting VEGF-BD/Cy5 bioconjugate was not cytotoxic to HEK293 cells engineered to express 2.5 × 106 VEGFR-2 per cell. Furthermore, it showed binding and activation of VEGFR-2 comparable with that of native VEGF. Internalization of VEGF-BD/Cy5 by PAE cells expressing 2.5 × 105 VEGFR-2 per cell was inhibited by excess VEGF, indicating a VEGFR-2-mediated mechanism of uptake. Near-IR fluorescent imaging of 4T1 mouse breast carcinoma revealed selective accumulation of VEGF-BD/Cy5, but not BD/Cy5, particularly at the tumor periphery where angiogenesis was most active. Accumulation of VEGF-BD/Cy5 in 4T1 breast carcinoma was diminished in mice pretreated with a toxin-VEGF fusion protein that selectively killed VEGFR-2-overexpressing endothelial cells. Our data lay the groundwork for future studies using the VEGF-BD/Cy5 bioconjugate as a targeting agent for BNCT of tumor neovasculature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Cited by
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
A review of NIR dyes in cancer targeting and imaging
Luo, S., Zhang, E., Su, Y., Cheng, T., & Shi, C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.06.024 · Cited by 1,432
Dai, Y., Xu, C., Sun, X., & Chen, X. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 931
Nanomaterials: Applications in Cancer Imaging and Therapy
Barreto, J. A., O’Malley, W., Kubeil, M., Graham, B., Stephan, H., & Spiccia, L. (2011) · Advanced Materials · doi:10.1002/adma.201100140 · Cited by 907
Dendrimer toxicity: Let's meet the challenge
Jain, K., Kesharwani, P., Gupta, U., & Jain, N. K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.04.027 · Cited by 710
Metadata
- Authors
- Backer, M. V., Gaynutdinov, T. I., Patel, V., Bandyopadhyaya, A. K., Thirumamagal, B. T. S., Tjarks, W., Barth, R. F., Claffey, K., & Backer, J. M.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2005-09-01
- Volume
- 4
- Issue
- 9
- Pages
- 1423-1429
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2126460855
- Cited by
- 180
- References
- 1
- FWCI
- 9.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. https://app.cochat.ai/papers/10.1158/1535-7163.mct-05-0161
- The paper
- Backer, M. V., Gaynutdinov, T. I., Patel, V., Bandyopadhyaya, A. K., Thirumamagal, B. T. S., Tjarks, W., Barth, R. F., Claffey, K., & Backer, J. M. (2005). Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-05-0161
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.